来源 | 复星 近日，由复星倾力打造的首届「复星杯」AI+创业创新大赛正式启动！依托复星及旗下 企业全球200+产业应用场景与雄厚资源，汇聚AI领域顶尖人才，探索前沿科技与产业的 深度融合。无论你是初创团队、高校科研力量，还是心怀梦想的AI开发者，这里都是你 展示创新成果、链接全球资源的舞台。 复星200+产业应用场景+千万投资 本届大赛优胜团队可获得： 招募赛道 本次大赛招募全国AI先锋，包括但不限于以下赛道： 1、AI+金融：深耕金融领域，直击业务痛点，需兼具技术实力（金融数据处理、自然语 言处理、机器学习）、行业洞察（熟悉市场、投资或交易逻辑）与成功经验（如数据分 析模型、智能投顾等案例）。 3、初赛：2 0 2 5年6月1 5日- 30日，2 0+企业晋级8强 2、AI+医药大健康：药物研发、临床开发、精准医疗、智能诊断、产业运营、AI药物研 发创新、智能临床开发系统、生物药生产智能化解决方案、精准医疗AI平台等，打造大 健康产业新范式。 3、AI+营销：探索AI技术在消费零售、文化传播、旅游体验等场景中的深度融合与创新 应用，助力精准营销与用户体验提升。 4、AI 4S：聚焦AI技术在科学领域的前沿 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-086 上海复星医药（集团）股份有限公司 关于控股子公司药品纳入突破性治疗药物程序的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 该新药为本集团（即本公司及控股子公司/单位，下同）自主研发的创新型小分 子化学药物，为 MEK1/2 选择性抑制剂，拟主要用于治疗晚期实体瘤、1 型神经纤维 瘤病、树突状细胞和组织细胞肿瘤、低级别脑胶质瘤等。 截至本公告日期（即 2025 年 5 月 12 日），该新药用于治疗成人树突状细胞和 组织细胞肿瘤、2 岁及 2 岁以上儿童 1 型神经纤维瘤病（NF1）相关的丛状神经纤维 瘤（PN）的药品上市注册申请均已获国家药监局受理并被纳入优先审评程序；该新 药用于治疗成人 1 型神经纤维瘤病于中国境内（不包括港澳台地区，下同）处于 III 期临床试验阶段，该新药用于低级别脑胶质瘤、颅外动静脉畸形、儿童朗格汉斯细 胞组织细胞增生症的治疗于中国境内均处于 II 期临床试验阶段，其中，该新药用于 治疗组织细胞肿瘤、无法手术或术 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7624.71 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.46% in the past month, 3.56% in the past three months, and 2.43% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI 300 Index, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.5%), WuXi AppTec (15.98%), Pian Zai Huang (6.77%), Yunnan Baiyao (5.51%), Kelun Pharmaceutical (4.73%), New Horizon (3.69%), East China Pharmaceutical (3.68%), Shanghai Raist (3.39%), Changchun High-tech (3.33%), and Fosun Pharma (3.23%) [1] - The market segment of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.75% and the Shenzhen Stock Exchange accounts for 36.25% [2] - In terms of industry composition, chemical drugs account for 43.27%, pharmaceutical and biotechnology services for 21.11%, traditional Chinese medicine for 19.35%, and biological drugs for 16.27% [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are fixed until the next scheduled adjustment unless a temporary adjustment is required [2] - Special events affecting sample companies may lead to changes in industry classification, and companies that are delisted will be removed from the index [2]

Major Events - Jin'an Industrial (02292) received a privatization offer from its controlling shareholder at a premium of approximately 30%, with resumption of trading on May 12 [1] - Jingtai Holdings (02228) plans to acquire 90% of Shanghai Siwei Medical for 250 million yuan, aiming to create an AI-enabled remote electrocardiogram diagnosis platform [1] - China Investment and Financing (01226) is in contact with MCHKI to explore several potential corporate activities following unusual stock price movements [1] - Qiu Tai Technology (01478) reported camera module sales of 33.229 million units in April, an increase of 8.4% month-on-month but a decrease of 20.1% year-on-year [1] - Stone Pharmaceutical Group (01093) received approval for clinical trials of SYH2046 in the United States [1] - Fosun Pharma (02196) subsidiary Junji Health obtained FDA approval for drug clinical trials [1] - Rongchang Bio (09995) received approval for the marketing of Aidiqi® for treating HER2-positive advanced breast cancer with liver metastasis in China [1] - Livzon Pharmaceutical (01513) received approval for the marketing of injectable aripiprazole microspheres [1] - GAC Group (02238) reported April automobile production of 108,600 units, a year-on-year decline of 25.74% [2] - China Overseas Development (00688) reported contract property sales of approximately 20.164 billion yuan in April, a year-on-year decrease of 7.5% [2] Share Buybacks/Reductions - China Hongqiao (01378) repurchased 19.667 million shares for 273 million HKD on May 9 [1] - AIA Group (01299) repurchased 1.5 million shares for 92.1915 million HKD on May 9 [1] - Cathay Securities (02611) repurchased 1.6906 million A-shares for 29.3356 million yuan on May 9 [1] - Times Electric (03898) repurchased 610,300 shares for 19.7008 million HKD on May 9 [1] - East Asia Bank (00023) acquired 52.8 million shares from Sumitomo Mitsui Banking Corporation [1] - Shandong Molong (00568) saw shareholder Zhimo Holdings reduce its holdings by 28.81 million H-shares [1] Operating Performance - Longyuan Power (00916) achieved a power generation volume of 6.9064 million MWh in April, a year-on-year increase of 4.85% [2] - New天绿色能源 (00956) reported a power generation volume of 1.4778 million MWh in April, a year-on-year increase of 16.91% [2] - Jianye Real Estate (00832) achieved a total property contract sales amount of 2.71 billion yuan in the first four months, a year-on-year increase of 4.8% [2] - China Overseas Hongyang Group (00081) reported a cumulative contract sales amount of 9.556 billion yuan in the first four months, a year-on-year decrease of 14.1% [2] - Times China Holdings (01233) reported a cumulative contract sales amount of approximately 1.81 billion yuan in the first four months, a year-on-year decrease of 29.87% [2] - Agile Property Holdings (01813) reported a pre-sale amount of 509 million yuan in April, a year-on-year decrease of 47.5% [2] - Greenland Hong Kong (00337) reported contract sales of approximately 880 million yuan in the first four months, a year-on-year decrease of 69.3% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司獲美國FDA藥品臨床試驗批准的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 董事長 陳玉卿 中國，上海 2025 年5 月9 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：6 ...

E-commerce - Suning.com held the 618 e-commerce launch meeting, with offline stores nationwide participating in the promotion starting from May 13, 2023 [1] - The online promotion will also begin on May 13, with multiple promotional events scheduled throughout the 618 period [1] Legal Actions - Italian company Moltiply has filed a lawsuit against Google's parent company Alphabet, seeking €2.97 billion (approximately $3.34 billion) in damages for alleged abuse of market dominance [2] - The lawsuit claims that Google's actions hindered the development of Moltiply's subsidiary, 7Pixel, from 2010 to 2017 [2] Retail and Sales - During the "Young Product New Venue" merchant conference, it was reported that 6,120 brands on the Dewu platform have doubled their annual sales [4] - Dewu has introduced policies to reduce fees for over 30 categories, with a maximum reduction of 16%, and has invested over 1 billion yuan in marketing rebates [4] Automotive Industry - The three major U.S. automakers criticized the trade agreement between President Trump and the UK, which allows UK manufacturers to export 100,000 cars to the U.S. at a 10% tariff rate [5] - This quota is nearly equivalent to the total number of cars exported from the UK last year, raising concerns among U.S. manufacturers about competitive disadvantages [5] Technology and AI - Nvidia has open-sourced several code reasoning models, including 32B, 14B, and 7B parameters, based on Alibaba's Qwen models [6] - Quark, Alibaba's AI application, is set to launch "Deep Search Pro," which aims to assist users in solving complex tasks across various professional fields [10] Aviation - International Airlines Group (IAG) announced the purchase of 53 new long-haul aircraft from Boeing and Airbus, including 32 Boeing 787-10s and 21 Airbus A330-900neos [11] Financial Services - Zhongzheng Asset Management (Jiangsu) Co., Ltd. completed a 30 million yuan angel round of financing to accelerate the development of its intelligent investment advisory platform [8] - The funds will be used for platform development, team expansion, and market outreach [8] Pharmaceuticals - Fosun Pharma's subsidiary received FDA approval to conduct clinical trials for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia [9] - The cumulative R&D investment for LBP-ShC4 is approximately 17 million yuan as of April 2025 [9] Regulatory Developments - The People's Bank of China plans to deepen financial reform and enhance the monetary policy framework to support high-quality financial development [12][14] - The China Securities Regulatory Commission aims to strengthen the regulation of capital market activities to maintain a fair market order [13]

关于控股子公司获美国 FDA 药品临床试验批准的公告 证券代码：600196 股票简称：复星医药 编号：临 2025-085 上海复星医药（集团）股份有限公司 截至 2025 年 4 月，本集团现阶段针对 LBP-ShC4 的累计研发投入约为人民币 0.17 亿元（未经审计）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海 菌济健康科技有限公司（以下简称"菌济健康"）收到美国 FDA（即美国食品药品 监督管理局）关于同意 LBP-ShC4 开展临床试验的批准。菌济健康拟于条件具备后开 展 LBP-ShC4 的 I 期临床试验。 二、LBP-ShC4 的研究情况 LBP-ShC4 为本集团（即本公司及控股子公司/单位，下同）自主研发的活体生 物治疗产品，拟用于治疗雄激素脱发（AGA）。 截至本公告日期（2025 年 5 月 9 日），于全球范围内尚无用于治疗雄激素脱发 （AGA）的活体生物治疗产品（包括单药或联合治疗方案）获批上市。 三、风险提示 ...

Core Viewpoint - The first "Fosun Cup" AI+ Entrepreneurship and Innovation Competition has been launched, aiming to integrate cutting-edge technology with industry applications, leveraging Fosun's extensive resources and global industry scenarios [1][10]. Group 1: Competition Overview - The competition is supported by Fosun's global investment institution, Fosun Ruijing Capital, which will provide investments ranging from 5 million to 50 million yuan for the top three teams [3][11]. - Winning teams will also gain priority access to over 200 industry application scenarios, including AI applications in finance, healthcare, and intelligent manufacturing [3][11]. - The competition includes cash prizes of 100,000 yuan or equivalent resources for the top teams, along with direct recruitment opportunities for outstanding teams [4][11]. Group 2: Recruitment Tracks - The competition is recruiting AI pioneers across various tracks, including AI+Finance, AI+Healthcare, AI+Marketing, AI for Science (AI4S), and AI+Intelligent Agents [4][11]. - Each track focuses on specific applications of AI, such as financial data processing, drug development, and intelligent marketing solutions [4][11]. Group 3: Competition Schedule - The project recruitment phase runs until June 15, 2025, followed by a selection process to identify over 20 enterprises for the initial round [6][7]. - The initial round will take place from June 15 to June 30, 2025, where 20+ enterprises will compete for a spot in the finals [7]. - The final competition is scheduled for July 2025, where experts and executives will evaluate the projects through presentations [8]. Group 4: Fosun's Strategic Focus - Fosun emphasizes technology innovation as a core strategic pillar, building a global innovation system that integrates independent research, investment incubation, and ecological cooperation [10][11]. - The company has made significant investments in AI and robotics, with a focus on enhancing efficiency in drug development, medical imaging, and precision medicine [10][12]. - Fosun's subsidiaries, including Fosun Pharma and Fosun Wealth Holdings, are actively integrating AI into their operations to improve decision-making, operational efficiency, and market insights [12][14].

根据《公司章程》的规定，董事长为复星医药的法定代表人。本次调整后，复星医药的法定代表人将变 更为陈玉卿。 资料显示，陈玉卿，1975年12月出生，现任复星医药执行董事、董事长（均自2025年4月29日起任）， 并于复星医药若干控股子公司担任董事、管理层职务。陈玉卿于2010年1月加入复星医药，其间曾历任 公司人力资源部总经理、总裁助理、副总裁、高级副总裁、联席总裁、联席首席执行官等；于2020年8 月至2021年5月及2022年10月至今任控股子公司上海复星健康科技（集团）有限公司董事长；于2024年9 月至2025年4月任复星医药非执行董事。陈玉卿现任香港联交所上市公司复星国际有限公司（股票代 码：00656，以下简称"复星国际"）高级副总裁，并曾任复星国际副总裁。 加入复星医药前，陈玉卿于1997年7月至1999年7月任上海大学材料学院教师，于1999年7月至2005年3月 历任延锋伟世通汽车饰件系统有限公司（现更名为延锋汽车饰件系统有限公司）、延锋伟世通（北京） 汽车饰件系统有限公司、上海延锋江森座椅有限公司人力资源经理，于2005年6月至2006年4月任上海埃 力生（集团）有限公司人力资源部发展经理， ...